Recombinant TrkA, B, C 抗体
Our Local Distributor
北京 101111
Quick Overview for Recombinant TrkA, B, C 抗体 (ABIN6945222)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
-
-
原理
- Trk A + B + C Recombinant Antibody
-
交叉反应
- 人, 小鼠, 大鼠
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from mouse Trk A
-
亚型
- IgG
-
-
anti-TrkA, B, C (AA 668-750) antibody
适用: 人 WB, IF (cc), IF (p), IHC (p), IHC (fro) 宿主: 兔 Polyclonal unconjugated
anti-TrkA, B, C (pTyr516) antibody适用: 大鼠 WB, IF (cc), IF (p), IHC (p), IHC (fro) 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
- WB(1:300-5000), IHC-P(1:20-100), IHC-F(1:100-500), IF(), ICC/IF(1:50-100)
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- Lot specific
-
缓冲液
- 0.01M TBS ( pH 7.4), 1 % BSA, 0.02 % Proclin 300, and 50 % Glycerol
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
-
有效期
- 12 months
-
-
- TrkA, B, C
-
别名
- TrkA+B+C
-
背景
-
Synonyms: BDNF/NT-3 growth factors receptor antibody, gp140trk antibody, GP145-TrkB antibody, GP145-TrkC antibody, High affinity nerve growth factor receptor antibody, MTC antibody, Neurotrophic tyrosine kinase receptor type 1 antibody, Neurotrophic tyrosine kinase receptor type 2 antibody, Neurotrophic tyrosine kinase receptor type 3 antibody, NT-3 growth factor receptor antibody, NTRK1 antibody, NTRK2 antibody, NTRK3 antibody, p140-TrkA antibody, TRK antibody, Trk-A antibody, Trk-B antibody, Trk-C antibody
Background: The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3. In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system. Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA. TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas. TrkB is overexpressed in tumors such as neuroblastoma, prostate adenocarcinoma and pancreatic ductal adenocarcinoma. In neuroblastomas overexpression of TrkB correlates with unfavorable disease outcome when autocrine loops signaling tumor survival are potentiated by additional overexpression of brain-derived neurotrophic factor (BDNF). An alternatively spliced truncated TrkB isoform lacking the kinase domain is overexpressed in Wilms tumors and this isoform may act as a dominant-negative to TrkB signaling. Altered TrkC expression and corresponding gene mutations are seen in various forms of cancer, with increased expression a positive prognostic indicator in patients with medulloblastoma.
-
UniProt
- P04629, Q16288, Q16620
抗原
-
